COVID-19 trials registries data warehouse

 Return to trial list

Trial - ISRCTN10942585


Column Value
Trial registration number ISRCTN10942585
Full text link
Last imported at : May 12, 2022, 1:30 a.m.
Source : International Clinical Trials Registry Platform (ICTRP)

First author
Last imported at : May 12, 2022, 1:30 a.m.
Source : International Clinical Trials Registry Platform (ICTRP)

Monika Klírová

Contact
Last imported at : May 12, 2022, 1:30 a.m.
Source : International Clinical Trials Registry Platform (ICTRP)

monika.klirova@nudz.cz

Registration date
Last imported at : May 12, 2022, 1:30 a.m.
Source : International Clinical Trials Registry Platform (ICTRP)

2022-05-06

Recruitment status
Last imported at : May 12, 2022, 1:30 a.m.
Source : International Clinical Trials Registry Platform (ICTRP)

Recruiting

Study design
Last imported at : May 12, 2022, 1:30 a.m.
Source : International Clinical Trials Registry Platform (ICTRP)

RCT

Allocation
Last imported at : May 12, 2022, 1:30 a.m.
Source : International Clinical Trials Registry Platform (ICTRP)

Randomized

Design
Last imported at : May 12, 2022, 1:30 a.m.
Source : International Clinical Trials Registry Platform (ICTRP)

Parallel

Masking
Last imported at : May 12, 2022, 1:30 a.m.
Source : International Clinical Trials Registry Platform (ICTRP)

Blind label

Center
Last imported at : May 12, 2022, 1:30 a.m.
Source : International Clinical Trials Registry Platform (ICTRP)

single-center

Study aim
Last imported at : May 12, 2022, 1:30 a.m.
Source : International Clinical Trials Registry Platform (ICTRP)

Long covid

Inclusion criteria
Last imported at : May 12, 2022, 1:30 a.m.
Source : International Clinical Trials Registry Platform (ICTRP)

1. Male and female outpatients aged 18-75 years with a history of COVID-19 and monitored by an outpatient physician for mental disorders (anxiety, mood disorders, sleep) within the PASC 2. PCR RNA SARS-CoV-2 negativity at screening/study entry 3. Duration of symptoms >1 and =18 months after detection of COVID-19 4. The mental ability to understand and sign the Informed Consent Form 5. Presence of neuropsychiatric PASC symptoms as determined by A-PASC with a minimum overall score =25 (cognitive score, emotional and functional impairment) 6. FIS questionnaire score =40 7. Psychopharmacological medication (if used) at a stable dose =4 weeks.

Exclusion criteria
Last imported at : May 12, 2022, 1:30 a.m.
Source : International Clinical Trials Registry Platform (ICTRP)

1. Contraindications of tDCS (skin disease, superficial injury, and fracture or infraction of skull in the stimulation area, epilepsy, metallic plates in the head) 2. History of any other DSM-IV axis I diagnosis prior to COVID-19, except for: 2.1. Depressive disorders, anxiety disorders, and sleep disorders that may be present in the history, but with at least 6 months of documented remission of symptoms 2.2. Disorders associated with the use of addictive substances at least 6 months before entering the study 3. Pregnancy or breastfeeding 4. Patients with severe and/or unstable somatic disorders (cardiovascular disease, neoplasms, endocrinology disorders, etc) 5. Patients suffering from a serious neurological disorder (eg epilepsy, head injury with loss of consciousness)

Number of arms
Last imported at : May 12, 2022, 1:30 a.m.
Source : International Clinical Trials Registry Platform (ICTRP)

2

Funding
Last imported at : May 12, 2022, 1:30 a.m.
Source : International Clinical Trials Registry Platform (ICTRP)

Czech Health Research Council

Inclusion age min
Last imported at : May 12, 2022, 1:30 a.m.
Source : International Clinical Trials Registry Platform (ICTRP)

18

Inclusion age max
Last imported at : May 12, 2022, 1:30 a.m.
Source : International Clinical Trials Registry Platform (ICTRP)

75

Countries
Last imported at : May 12, 2022, 1:30 a.m.
Source : International Clinical Trials Registry Platform (ICTRP)

Czech Republic

Type of patients
Last imported at : May 12, 2022, 1:30 a.m.
Source : International Clinical Trials Registry Platform (ICTRP)

Patients recovered from covid

Severity scale
Last imported at : May 12, 2022, 1:30 a.m.
Source : International Clinical Trials Registry Platform (ICTRP)

N/A

Total sample size
Last imported at : May 12, 2022, 1:30 a.m.
Source : International Clinical Trials Registry Platform (ICTRP)

34

primary outcome
Last imported at : May 12, 2022, 1:30 a.m.
Source : International Clinical Trials Registry Platform (ICTRP)

Czech version of the “Fatigue Impact Scale“ (FIS) score after the acute phase of the study and after the 4W-FU

Notes
Last imported at : May 12, 2022, 1:30 a.m.
Source : International Clinical Trials Registry Platform (ICTRP)

Phase
Last imported at : May 12, 2022, 1:30 a.m.
Source : International Clinical Trials Registry Platform (ICTRP)

Not reported

Arms
Last imported at : May 12, 2022, 1:30 a.m.
Source : International Clinical Trials Registry Platform (ICTRP)

[{"arm_notes": "", "treatment_id": 2484, "treatment_name": "Anodal tdcs", "treatment_type": "Rehabilitation", "pharmacological_treatment": "Non pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}]